Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Collins

Showing results (51-60 of 103) with videos related to

Pageof 11
Sort By:
Journal of Medicinal Chemistry|April 25, 2007
Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based designAlastair Donald, Tatiana McHardy, Martin G Rowlands, et al.
Cancer Research|March 5, 2022
Genome-Protective Topoisomerase 2a-Dependent G2 Arrest Requires p53 in hTERT-Positive Cancer CellsNicola Lockwood, Silvia Martini, Ainara Lopez-Pardo, et al.
Metabolomics : Official Journal of the Metabolomic Society|April 15, 2020
Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients are associated with NOS regulationAkos Pal, Yasmin Asad, Ruth Ruddle, et al.
Cancer Research|January 18, 2011
CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitorsVictoria E Anderson, Michael I Walton, Paul D Eve, et al.
Molecules (Basel, Switzerland)|February 15, 2022
Discovery and Characterization of a Cryptic Secondary Binding Site in the Molecular Chaperone HSP70Suzanne O'Connor, Yann-Vaï Le Bihan, Isaac M Westwood, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|March 2, 2016
Synthesis and Evaluation of a 2,11-Cembranoid-Inspired LibraryAmanda J Welford, John J Caldwell, Manjuan Liu, et al.
Australian Journal of Primary Health|February 24, 2015
Transitioning to routine breast cancer risk assessment and management in primary care: what can we learn from cardiovascular disease?Kelly-Anne Phillips, Emma J Steel, Ian Collins, et al.
Journal of Molecular Biology|February 6, 2007
A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimeraThomas G Davies, Marcel L Verdonk, Brent Graham, et al.
International Journal of Radiation Oncology, Biology, Physics|September 18, 2012
Targeted radiosensitization by the Chk1 inhibitor SAR-020106Gerben R Borst, Martin McLaughlin, Joan N Kyula, et al.
Journal of Medicinal Chemistry|April 28, 2016
Exploiting Protein Conformational Change to Optimize Adenosine-Derived Inhibitors of HSP70Matthew D Cheeseman, Isaac M Westwood, Olivier Barbeau, et al.
Pageof 11

Showing results (51-60 of 103) with videos related to

Sort By:
Pageof 11
Journal of Medicinal Chemistry|April 25, 2007
Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based designAlastair Donald, Tatiana McHardy, Martin G Rowlands, et al.
Cancer Research|March 5, 2022
Genome-Protective Topoisomerase 2a-Dependent G2 Arrest Requires p53 in hTERT-Positive Cancer CellsNicola Lockwood, Silvia Martini, Ainara Lopez-Pardo, et al.
Metabolomics : Official Journal of the Metabolomic Society|April 15, 2020
Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients are associated with NOS regulationAkos Pal, Yasmin Asad, Ruth Ruddle, et al.
Cancer Research|January 18, 2011
CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitorsVictoria E Anderson, Michael I Walton, Paul D Eve, et al.
Molecules (Basel, Switzerland)|February 15, 2022
Discovery and Characterization of a Cryptic Secondary Binding Site in the Molecular Chaperone HSP70Suzanne O'Connor, Yann-Vaï Le Bihan, Isaac M Westwood, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|March 2, 2016
Synthesis and Evaluation of a 2,11-Cembranoid-Inspired LibraryAmanda J Welford, John J Caldwell, Manjuan Liu, et al.
Australian Journal of Primary Health|February 24, 2015
Transitioning to routine breast cancer risk assessment and management in primary care: what can we learn from cardiovascular disease?Kelly-Anne Phillips, Emma J Steel, Ian Collins, et al.
Journal of Molecular Biology|February 6, 2007
A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimeraThomas G Davies, Marcel L Verdonk, Brent Graham, et al.
International Journal of Radiation Oncology, Biology, Physics|September 18, 2012
Targeted radiosensitization by the Chk1 inhibitor SAR-020106Gerben R Borst, Martin McLaughlin, Joan N Kyula, et al.
Journal of Medicinal Chemistry|April 28, 2016
Exploiting Protein Conformational Change to Optimize Adenosine-Derived Inhibitors of HSP70Matthew D Cheeseman, Isaac M Westwood, Olivier Barbeau, et al.
Pageof 11